A Study of Tecogalan Sodium
This study has been completed.
Information provided by:
NIH AIDS Clinical Trials Information Service
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: April 1996
To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152) and to establish the MTD at each of the different dosing schedules.
|Study Design:||Endpoint Classification: Safety Study
Primary Purpose: Treatment
|Official Title:||A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Twice Weekly for 21 Days|
Resource links provided by NLM:
Genetic and Rare Diseases Information Center resources: Malignant Mesenchymal Tumor Soft Tissue SarcomaU.S. FDA Resources
Further study details as provided by NIH AIDS Clinical Trials Information Service:
Contacts and Locations